HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Doxazosin (Cardura)

A prazosin-related compound that is a selective alpha-1-adrenergic blocker.

Also Known As:

Cardura; 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine; Alfamedin; Aliud Brand of Doxazosin Mesylate; Almirall Brand of Doxazosin Mesylate; Alpharma Brand of Doxazosin Mesylate; Alter Brand of Doxazosin Mesylate; Apo-Doxazosin; Apogepha Brand of Doxazosin Mesylate; Apotex Brand of Doxazosin Mesylate; AstraZeneca Brand of Doxazosin Mesylate; Azupharma Brand of Doxazosin Mesylate; Cantabria Brand of Doxazosin Mesylate; Cardular; Carduran; Carduran Neo; Ciclum Brand of Doxazosin Mesylate; Cinfa Brand of Doxazosin Mesylate; Combino Brand of Doxazosin Mesylate; Diblocin; Doxa-Puren; DoxaUro; Doxacor; Doxagamma; Doxamax; Doxatensa; Doxazomerck; Doxazosin AL; Doxazosin AZU; Doxazosin Apogepha; Doxazosin Heumann; Doxazosin Klast; Doxazosin Monohydrochloride; Doxazosin Stada; Doxazosin beta; Doxazosin findusFit; Doxazosin-Wolff; Doxazosin-ratiopharm; Doxazosina Alter; Doxazosina Cinfa; Doxazosina Combino Pharm; Doxazosina Geminis; Doxazosina Normon; Doxazosina Pharmagenus; Doxazosina Ratiopharm; Doxazosina Ur; Geminis Brand of Doxazosin Mesylate; Gen-Doxazosin; Genpharm Brand of Doxazosin Mesylate; Heumann Brand of Doxazosin Mesylate; Hexal Brand of Doxazosin Mesylate; Juta Brand of Doxazosin Mesylate; Jutalar; Kade Brand of Doxazosin Mesylate; Linden Brand of Doxazosin Mesylate; MTW Brand of Doxazosin Mesylate; MTW-Doxazosin; Merck dura Brand of Doxazosin Mesylate; Normon Brand of Doxazosin Mesylate; Novo-Doxazosin; Novopharm Brand of Doxazosin Mesylate; Pfizer Brand of Doxazosin Mesylate; Pharmagenus Brand of Doxazosin Mesylate; Progandol Neo; Q-Pharm Brand of Doxazosin Mesylate; Ratiopharm Brand of Doxazosin Mesylate; Solvay Brand of Doxazosin Mesylate; Stadapharm Brand of Doxazosin; TAD Brand of Doxazosin Mesylate; UK-33274; Uriduct; Wolff Brand of Doxazosin Mesylate; Wörwag Brand of Doxazosin Mesylate; Zoxan; betapharm Brand of Doxazosin Mesylate; ct-Arzneimittel Brand of Doxazosin Mesylate; doxazosin von ct; esparma Brand of Doxazosin Mesylate; findusFit Brand of Doxazosin Mesylate; ratio-Doxazosin; Apo Doxazosin; Doxa Puren; Doxazosin Wolff; Doxazosin ratiopharm; Gen Doxazosin; MTW Doxazosin; Mesylate, Doxazosin; Monohydrochloride, Doxazosin; Neo, Carduran; Novo Doxazosin; Q Pharm Brand of Doxazosin Mesylate; Ratiopharm, Doxazosina; UK 33274; UK33274; ct Arzneimittel Brand of Doxazosin Mesylate; ratio Doxazosin; Doxazosin Mesylate; Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)-

Networked: 675 relevant articles (83 outcomes, 176 trials/studies)

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 60
- 2-Ring Heterocyclic Compounds
  - Quinazolines: 29
    - Prazosin: 1512
      - Doxazosin: 675
        2-(4-(biphenyl-4-sulfonyl)-piperazin-1-yl)-6,7-dipropoxyquinazolin-4-yl-amine
        6-hydroxydoxazosin
        7-hydroxydoxazosin

Experts

1.	Kyprianou, Natasha: 14 articles (05/2011 - 01/2002)
2.	Davis, Barry R: 10 articles (12/2012 - 09/2002)
3.	ALLHAT Collaborative Research Group: 8 articles (11/2009 - 02/2001)
4.	Kaplan, Steven A: 7 articles (12/2015 - 12/2003)
5.	Black, Henry R: 7 articles (05/2009 - 01/2002)
6.	Kusek, John W: 6 articles (06/2014 - 12/2003)
7.	Kirby, R S: 6 articles (01/2005 - 07/2000)
8.	Roehrborn, Claus G: 5 articles (09/2008 - 12/2003)
9.	Kyprianou, N: 5 articles (05/2003 - 01/2000)
10.	Michel, Martin C: 4 articles (09/2014 - 01/2006)

Related Diseases

1.	Hypertension (High Blood Pressure) 08/16/1989 - "This unique combination of antihypertensive efficacy and favorable effect on blood lipid levels indicates that once-daily treatment with doxazosin holds considerable promise in the treatment of hypertension, both from the point of view of its antihypertensive efficacy and also from its primary preventative potential." 05/01/2000 - "These findings demonstrate that doxazosin add-on therapy is an effective, well-tolerated treatment strategy for patients with inadequately controlled hypertension." 01/01/1995 - "Thus, it can be concluded doxazosin is an effective and well tolerated treatment for BPH which appears to have additional benefits in the management of patients with concomitant hypertension." 10/01/1990 - "Doxazosin was well tolerated and was shown to be effective as monotherapy in mild and moderate hypertension. " 05/29/1987 - "Doxazosin is a once-daily, long-acting, selective alpha 1-adrenergic inhibitor that is effective for the treatment of essential hypertension. "
2.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 06/10/2005 - "These findings, that demonstrate chronic doxazosin administration causes significant changes in the expression of several hundred genes in the rat prostate, may provide insight into the long-term efficacy of alpha1-AR antagonists in the treatment of benign prostatic hyperplasia." 01/01/2015 - "To compare the efficacy of 4 mg and 8 mg doxazosin XL treatments in patients with benign prostatic hyperplasia-related lower urinary tract symptoms and determine the efficiency of 8 mg in those patients with inadequate response to 4 mg. A total of 162 patients were included in this study. " 09/01/1996 - "Safety and efficacy of doxazosin in benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies." 03/01/1994 - "In a placebo-controlled study, the safety and efficacy of the selective alpha 1-adrenoceptor-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia (BPH) were evaluated. " 01/01/1993 - "The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. "
3.	Heart Failure 07/01/2001 - "I've been taking Cardura and it's helped a lot, but my doctor stopped it because he said a study found the drug could cause heart failure. " 08/01/2009 - "Safety and efficacy of doxazosin as an "add-on" antihypertensive therapy in mild to moderate heart failure patients." 09/01/2010 - "Furthermore, use of doxazosin in ASCOT was not associated with an increased risk of heart failure, in contrast to the earlier finding of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). " 10/01/2005 - "A double-blind, randomized study was conducted on 30 patients with chronic congestive heart failure (NYHA III-IV), with cardiac index<2.5 l/minxm, and/or with pulmonary capillary wedge pressure>16 mm Hg. Of the 30 patients, 15 were treated with doxazosin and 15 with placebo, both adjuvant to stable oral therapy, which included a minimum of an ACE inhibitor and a diuretic. " 04/01/2001 - "The doxazosin arm of the ALLHAT study was terminated by the data monitoring and safety board because the doxazosin-treated patients developed congestive heart failure at a greater rate than diuretic-treated patients. "
4.	Erectile Dysfunction 11/01/2009 - "In this study we aimed to evaluate the impact of doxazosin treatment on erectile functions in patients with lower urinary tract symptoms (LUTS) and having erectile dysfunction (ED) at baseline. " 03/01/2015 - "With doxazosin, the incidence was 5.8% vs. 3.3% for erectile dysfunction, 3.6% vs. 1.9% for reduced libido and 0.4% vs. 1.4% for ejaculatory disorders. " 09/01/2011 - "Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms." 01/01/2005 - "To report a comprehensive retrospective analysis of the favourable effects of doxazosin extended-release (XL) and doxazosin standard on the sexual health of patients with comorbid benign prostatic hyperplasia (BPH) and erectile dysfunction (ED), augmenting a previous study of 680 patients with symptomatic BPH. " 09/01/2008 - "Patients with benign prostatic hyperplasia and erectile dysfunction treated with the doxazosin gastrointestinal therapeutic system on a regular basis, with no other antihypertensive events, were recruited. "
5.	Prostatitis 01/01/2002 - "A total of 60 men with chronic non-bacterial prostatitis were randomised to daily supplement of 4 mg doxazosin or a placebo, for 3 months. " 01/01/2002 - "The efficacy of doxazosin monotherapy in chronic non-bacterial prostatitis was investigated in terms of urinary symptom, pain and quality of life assessment versus placebo. " 01/01/2002 - "Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo." 01/01/2008 - "For a 6-week short-term treatment levofloxacin is more effective than doxazosin for chronic prostatitis/chronic pelvic pain syndrome. " 01/01/2008 - "We performed a prospective, randomized study to examine the efficacies of levofloxacin and doxazosin alone and as a combination therapy in patients with National Institutes of Health (NIH) category III chronic prostatitis/chronic pelvic pain syndrome. "

Related Drugs and Biologics

1.	Terazosin (Hytrin)
2.	Finasteride (Propecia)
3.	Atenolol (Tenormin)
4.	tamsulosin (Flomax)
5.	Lipids
6.	Glucose (Dextrose)
7.	Adrenergic Antagonists (Antiadrenergic Agents)
8.	Prazosin (Minipress)
9.	Antihypertensive Agents (Antihypertensives)
10.	sildenafil (Viagra)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Massage (Reflexology)
3.	Psychology Biofeedback (Biofeedback)
4.	Kidney Transplantation
5.	Prostatectomy (Retropubic Prostatectomy)